Soligenix Inc (SNGX)

Apr 15, 2026

Soligenix secures EU orphan drug designation for Behçet’s disease therapy - MSN

Apr 15, 2026

Apr 14, 2026

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.

Apr 14, 2026

Apr 13, 2026

BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

Apr 13, 2026

Apr 13, 2026

Hedge Fund Bets: Can Soligenix Inc be the next market leader2026 Top Decliners & Long-Term Safe Return Strategies - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Mycosis Fungoides Treatment Market Surges to US$ 3.42 Billion - openPR.com

Apr 11, 2026

Apr 10, 2026

Aug Chart Watch: What is the next catalyst for Soligenix IncBond Market & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Technical Analysis: Can Soligenix Inc be the next market leader2026 Dividend Review & AI Enhanced Trading Signals - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

SNGX: Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data - TradingView — Track All Markets

Apr 08, 2026

Apr 06, 2026

SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26 - Zacks Small Cap Research

Apr 06, 2026

Apr 06, 2026

Stock Recap: Is Soligenix Inc a speculative investmentPortfolio Update Report & Reliable Entry Point Alerts - baoquankhu1.vn

Apr 06, 2026

Apr 03, 2026

Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - The Globe and Mail

Apr 03, 2026

Apr 03, 2026

[EFFECT] SOLIGENIX, INC. SEC Filing - Stock Titan

Apr 03, 2026

Apr 03, 2026

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - Sahm

Apr 03, 2026

Apr 02, 2026

Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - NewMediaWire

Apr 02, 2026

Apr 02, 2026

Soligenix (SNGX) Announces Positive Study Results for HyBryte in CTCL Treatment - GuruFocus

Apr 02, 2026

Apr 02, 2026

Positive Clinical Results from HyBryte™ Comparative Study Evalua - GuruFocus

Apr 02, 2026

Apr 02, 2026

HyBryte study shows faster response vs Valchlor in lymphoma trial By Investing.com - Investing.com Canada

Apr 02, 2026

Apr 02, 2026

HyBryte study shows faster response vs Valchlor in lymphoma trial - Investing.com

Apr 02, 2026

Apr 01, 2026

Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - NewMediaWire

Apr 01, 2026

Apr 01, 2026

Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - TipRanks

Apr 01, 2026

Apr 01, 2026

Soligenix reports 2025 results, eyes Q2 trial data By Investing.com - Investing.com South Africa

Apr 01, 2026

Mar 31, 2026

Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets

Mar 31, 2026

Mar 31, 2026

Soligenix (NASDAQ: SNGX) registers 1,054,688 resale shares from warrants - Stock Titan

Mar 31, 2026

Mar 31, 2026

Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 31, 2026

Mar 31, 2026

Soligenix (SNGX) 2025 10-K outlines CTCL, psoriasis and vaccine programs - Stock Titan

Mar 31, 2026

Mar 31, 2026

Buybacks Report: Can Soligenix Inc grow without external funding2026 Volatility Report & Safe Entry Trade Reports - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - Bitget

Mar 31, 2026

Mar 31, 2026

Soligenix reports 2025 results, eyes Q2 trial data - Investing.com

Mar 31, 2026

Mar 31, 2026

Soligenix announces recent accomplishments and year end 2025 financial results - marketscreener.com

Mar 31, 2026

Mar 31, 2026

Soligenix Announces Recent Accomplishments And Year End 2025 Financial Results - TradingView

Mar 31, 2026

Mar 30, 2026

Retail Trends: What analysts say about Soligenix Inc stockGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn

Mar 30, 2026

Mar 30, 2026

Aug Sectors: Is Soligenix Inc a strong candidate for buy and holdMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn

Mar 30, 2026

Mar 30, 2026

Soligenix, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 30, 2026

Mar 29, 2026

Guidance Update: Will Soligenix Inc benefit from rising consumer demand2026 Highlights & AI Forecasted Stock Moves - baoquankhu1.vn

Mar 29, 2026

Mar 27, 2026

Stock List: Research Stocks from Around the World - GuruFocus

Mar 27, 2026

Mar 27, 2026

Soligenix receives EU orphan drug status for Behçet’s treatment By Investing.com - Investing.com South Africa

Mar 27, 2026

Mar 26, 2026

Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet Disease - NewMediaWire

Mar 26, 2026

Mar 26, 2026

Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease - Benzinga

Mar 26, 2026

Mar 26, 2026

Soligenix (SNGX) Gains EU Orphan Drug Designation for Dusquetide in Behcet's Disease - GuruFocus

Mar 26, 2026

Mar 26, 2026

Soligenix receives EU orphan drug status for Behçet’s treatment - Investing.com

Mar 26, 2026

Mar 26, 2026

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease - Lelezard

Mar 26, 2026

Mar 26, 2026

SNGX: Late-stage rare disease therapies and vaccines show strong clinical and commercial promise - TradingView — Track All Markets

Mar 26, 2026

Mar 25, 2026

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behcet's Disease - Bitget

Mar 25, 2026

Mar 25, 2026

Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - NewMediaWire

Mar 25, 2026

Mar 25, 2026

Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - TradingView

Mar 25, 2026